MedTrace Logo

Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI

NCT07736261 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-07-30

No results posted yet for this study

Summary

Participants will:

* Take either drospirenone (a daily pill) or the standard daily injection during their ovarian stimulation cycle, alongside their regular fertility hormone injections
* Undergo egg retrieval, with all resulting embryos frozen (no fresh embryo transfer in this study)
* Have a frozen embryo transferred in a later cycle
* Complete two short questionnaires about their treatment experience - once before starting the injections/pills, and once after the stimulation phase ends
* Be followed to determine if the embryo transfer results in a pregnancy

Conditions

  • Poor Ovarian Reserve
  • Infertility (IVF Patients)

Interventions

DRUG

Drospirenone drug

A drug drospirenone in the form of 1 tablet / d from 14 mm follicle till hCG trigger day

DRUG

Cetrorelix 0.25 mg

Cetrorelix a drug injection daily sc. from 14 mm follicle till hCG trigger day

Sponsors & Collaborators

  • Ahmed Saad

    lead OTHER

Principal Investigators

  • Ahmed s Saad, phD · Professor of OB & GYN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-10-31
Completion
2027-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07736261 on ClinicalTrials.gov